Thomas Civik

CIK: 0001723092

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PYXS

Pyxis Oncology, Inc.

DirectorOfficer

RPTX

Repare Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

PYXS
Pyxis Oncology, Inc.
Sep 4, 2026
Award(A)
Stock Option (Right to Buy)
Direct
2.5M shares-
PYXS
Pyxis Oncology, Inc.
Aug 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
251K shares-
PYXS
Pyxis Oncology, Inc.
Feb 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
690.1K shares-
RPTX
Repare Therapeutics Inc.
Jan 28, 2026
Disposition(D)
Direct
7.5K shares-
PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
37K shares at avg. $0.98-

		Type	Shares	Price		Ownership
Sep 4, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	2,503,050	-	-	Direct
Aug 12, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	250,956	-	-	Direct
Feb 3, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	690,131	-	-	Direct
Jan 28, 2026	RPTX Repare Therapeutics Inc.	Disposition(D)	7,500	-	$0	Direct
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	36,979	$0.98	-	Direct

1-5 of 5 transactions

About Civik Thomas

Civik Thomas (SEC CIK 0001723092) files insider reports with the SEC as CEO & Chairman of the Board of Pyxis Oncology, Inc. (PYXS) and Director of Repare Therapeutics Inc. (RPTX).

Signal8 holds 5 ownership filings by Civik Thomas, all Form 4s, filed between Apr 2, 2025 and Sep 8, 2026. Those filings report 5 transactions, from Mar 31, 2025 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Civik Thomas's filings is in BOSTON, MA.

Recent filings by Civik Thomas

Sep 4, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Aug 12, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Feb 3, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Jan 28, 2026: Disposition to issuer transaction of RPTX shares (Form 4, code D).
Mar 31, 2025: Grant or award of PYXS derivative securities (Form 4, code A).

Other insiders filing for Pyxis Oncology, Inc. (PYXS)

GordonMD Global Investments LP, 10% Owner
Dupont Jakob, Director
Wadhane Jitendra, Prin Fin & Acct Officer
FLAVIN JOHN L, Director
Metzger Michael A, Director
Lewis-Hall Freda C, Director

How to read Form 4 transaction codes